Статья
Особенности фармакотерапии пациентов с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка
Обзор посвящен фармакотерапии хронической сердечной недостаточности (ХСН) с сохраненной фракцией выброса левого желудочка. Обсуждаются данные ряда мета-анализов, рандомизированных и наблюдательных клинических исследований, а также показания к применению блокаторов ренин-ангиотензин-альдостероновой системы, ß-адреноблокаторов, антагонистов минералокортикоидных рецепторов у пациентов этой категории в современных клинических рекомендациях. Рассмотрены новые перспективные подходы к терапии ХСН с позиции влияния на кардиальный фиброз.
1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet 2015;385:812-824.
2. Owan T., Redfield M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-332.
3. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
4. Tribouilloy C., Rusinaru D., Mahjoub H. et al. Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2008; 29:339-347.
5. Mareev V. Yu., Dangiyeliang M. O., Belenkov Yu. N. On behalf of the working group of research EPOHA-O-HSN. The comparative characteristic of patients with HSN depending on size FV by results of the Russian multicenter research EPOHA-O-HSN. Heart Failure 2006; 7 (4):164-171. Russian (Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ ЛЖ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность 2006;7 (4):164-171).
6. Metra M. June 2016 at a glance: epidemiology, renal impairment, heart failure with preserved ejection fraction. Eur J Heart Fail 2016;18 (6):587.
7. Martos R., Baugh J., Ledwidge M. et al. Evidence of Increased Myocardial Collagen Turnover Linked to Diastolic Dysfunction. Circulation 2007;115:888-895.
8. McMurray J., Carson P., Komajda M. et al. Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008;10:149-156.
9. Ponikowski P., Voors A., Anker S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur HeartJ 2016; doi:10.1093/eur-heartj/ehw128.
10. Lam C., Solomon S. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Нeart Fail 2014;16:1049-1055.
11. Lund L. Heart Failure With “Mid-Range" Ejection Fraction-New Opportunities. J Card Fail 2016;22 (10):769-771.
12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;4;316 (23):1429-1435.
13. Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J Renin Angiotensin Aldosterone Syst 2001;2: S4-7.
14. Nagai T., Nitta K., Kanasaki M. et al. The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clin Exp Nehrol 2015;19 (1):65-74.
15. DAmore A., Black M., Thomas W. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005;46:1347-1354.
16. Haulica I., Walther Bild W., Serban D. Review: Angiotensin Peptides and their Pleiotropic Actions. J Renin Angiotensin Aldosterone Syst 2005;6:121-131.
17. Agarwal V., Briasoulis A., Messerli F. Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev 2013;18:429-437.
18. Chatterjee S., Biondi-Zoccai G., Abbate A. et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346: f596.
19. Pitt B., Pfeffer M., Assmann S. et al. for the TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392.
20. Pandey A., Garg S., Matulevicius S. et al. Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. J Am Heart Assoc 2015; 4: e002137.
21. Chen Y., Wang H., Lu Y. et al. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Medicine 2015;13:10.
22. Roger V. Epidemiology of heart failure. Circ Res 2013;6:646-659.
23. Piek A., de Boer R., Sillje H. The fibrosis-cell death axis in heart failure. Heart Fail Rev 2016;21:199-211.
24. Gwathmey J., Yerevanian A., Hajjar R. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. Hum Gene Ther 2013;11:937-947.
25. Liu L., Dorhout B., van der Meer P. et al. Omecamtiv mecarbil: a novel cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs 2016;25:117-127.
26. Park M., Vatner S., Yan L. et al. Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload. Basic Res Cardiol 2013;108:324.
27. Flather M., Shibata M., Coats A. et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.
28. van Veldhuisen D., Cohen-Solal А., Böhm M. et al. SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-2158.
29. Liu F., Chen Y., Feng X. et al. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One 2014;9 (3):e90555.
30. Bavishi C., Chatterjee S., Ather S. et al. Patel D., Messerli F. Betablockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 2015;20 (2):193-201.
31. Pitt B., Zannad F., Remme W. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
32. Zannad F., McMurray J., Krum H. et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.